|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | One hundred years of research in the pathogenesis of pulmonary hypertension显示文摘 | Zaiman A Fijalkowska L Hassoun PM | 2005 | Am J Respir Cell Mol Biol2005，33，5： | 1 |
| 2 | One hundred years of research in the pathogenesis of pulmonary hypertension 显示文摘 | Zaiman A Fijalkowska L Hassoun PM | 2005 | Am J Respir Cell Mol Biol2005，33，5： | 1 |
| 3 | One hundred years of research in The pathogenesis of pulmonary hypertension 显示文摘 | Zaiman A Fijalkowska I Hassoun PM | 2005 | Am J Respir Cell Mol Biol2005，33，5： | 1 |
| 4 | Health-related quality of life following transcatheter aortic valve implantation using transaortic, transfemoral approaches and surgical aortic valve replacement-a single-center study显示文摘Objective To evaluate short- and long-term changes in quality of life (QoL) in patients undergoing transcatheter aortic valve implantation (TAVI) and to assess differences in patient QoL when using the TAVI transaortic (TAVI TAo) approach compared with the transfemoral approach (TAVI TF) and surgical aortic valve replacement (SAVR). Methods Ninety-seven patients were assessed. Thirty-two patients underwent TAVI TAo, 31 underwent TAVI TF and 34 patients underwent SAVR. QoL was assessed using the EQ-5D-3L questionnaire at baseline, after one month and one year. Results Mean patient age was 80 years (range, 61–92 years) and the mean logistic EuroSCORE was 12.45%(range, 1.39%?78.98%). Declared health state at baseline was significantly lower in TAVI TF (P < 0.001) and after one month there were no differences between the three groups (P = 0.99). After one year, SAVR patient results of the EQ-5D-3L index value were lower in comparison to both TAVI patient groups (P < 0.05). The analysis also showed significant differences between the results of EQ-5D-3L index value over the one month and one year follow-up (TAVI TAo, P < 0.001;TAVI TF, P < 0.05;SAVR, P < 0.05). In all groups, the values significantly increased after one-month and one-year of follow-up in comparison to baseline value. Significant differences were also demonstrated between Visual Analogue Scale values (VAS). Conclusions A significant improvement in QoL was observed in all three patient groups. Regardless of the TAVI approach, EQ-5D-3L and VAS values were significantly increased after one-month and one-year follow up;the SAVR patients however, reported lower health status when compared to the TAVI patients. | Aleksandra Stańska Dariusz Jagielak Maciej Kowalik Maciej Brzeziński Rafal Pawlaczyk Jadwiga Fijalkowska Wojciech Karolak Jan Rogowski Peter Bramlage | 2018 | Journal of Geriatric Cardiology2018，15，11： | 1 |
| 5 | Hormonal activity of the hypophysial - gonadal axis versus the mineral bone density and specific markers of bone turnover in haemodialysis population 显示文摘 | Kurnatowska I Zygmunt A Fijalkowska - Morawska J | 2006 | Pol Merkur Lekarski2006，20，118： | 1 |
| 6 | Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension显示文摘 | Fijalkowska A Kurzyna M Torbicki A | 2006 | Chest2006，129，： | 1 |
| 7 | Mannosylated lipoarabinomannan balances apoptosis and inflammatory state in mycobacteria-infected and uninfected bystander macrophages 显示文摘 | Wojtas B Fijalkowska B Wlodarczyk A | 2011 | Microb Pathog2011，51，12： | 1 |
| 8 | Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension 显示文摘 | Fijalkowska A Kurzyna M Torbicki A | 2006 | Chest2006，129，5： | 1 |
| 9 | D-dimer in diagnosis and treatment of pulmonary embolism显示文摘 | Fijalkowska A | 2009 | Pneumonol Alergol Pol2009，77，3： | 1 |
| 10 | Serum N-terminal brain natri- uretic peptide as a prognostic parameter in patients with pulmonary hyperten- sion显示文摘 | Fijalkowska A Kurzyna M Torbicki A | 2006 | Chest2006，129，： | 1 |
| 11 | Serum N- terminal brain natriuretic peptide as a prog nostic parameter in patients with pulmonary hypertension 显示文摘 | FIJALKOWSKA A KURZYNA M TORBICKI A | 2006 | Chest2006，129，5： | 1 |
| 12 | Cerebrospinal fluid and blood propofol concentration during total intravenous anaesthesia for neurosurgery 显示文摘 | Dawidowicz AL Fijalkowska A Nestorowicz A | 2003 | Br J Anaesth2003，90，1： | 1 |
| 13 | Diagnosis of malignant pericarditis : a single centre experience 显示文摘 | Pawlak Ciealik A Szturmowicz M Fijalkowska A | 2012 | Kardiol Pol2012，70，11： | 1 |
| 14 | alpha-1 Antitrypsin in- hibits caspase-3 activity, preventing lung endothelial cell apoptosis 显示文摘 | Petrache I Fijalkowska I Medler TR | 2006 | Am J Pathol2006，169，4： | 1 |
| 15 | One hundred years of research in the pathogenesis of pulmonary hypertension显示文摘 | Zaiman A Fijalkowska L Hassoun PM | 2005 | Am J Respir Cell Mol Biol2005，33，5： | 1 |
| 16 | Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion显示文摘 | W. Tomkowski M. Szturmowicz A. Fijalkowska S. Filipecki E. Figura-Chojak | 1994 | Journal of Cancer Research and Clinical Oncology1994，，7： | 1 |
| 17 | Unequal fidelity of leading and lagging strand DNA replication on the Escherichia coli chromosome显示文摘 | Jonczyk P Tkaczyk M M | 1998 | Proc Natl Acad Sci USA1998，95，10： | 1 |
| 18 | Pathology of Pulmonary Hypertension显示文摘 | Rubin M. Tuder John C. Marecki Amy Richter Iwona Fijalkowska Sonia Flores | 2007 | Clinics in Chest Medicine2007，，1： | 1 |
| 19 | One hundred years of research in the pathogenesis of pulmonary hypertension显示文摘 | ZAIMAN A FIJALKOWSKA L HASSOUN PM | 2005 | Am J Respir Cell Mol Bioi2005，33，5： | 1 |
| 20 | One hundred years of research in the pathogenesis of pulmonary hypertension显示文摘 | Zaiman A Fijalkowska I Hassoun PM | 2005 | Respir Cell Mol Biol2005，33，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员